248 related articles for article (PubMed ID: 31879092)
1. [Regression of cutaneous basal cell and squamous cell carcinoma under pembrolizumab].
Delaitre L; Martins-Héricher J; Truchot E; Denis D; Prophette B; Maillard H; Bénéton-Benhard N
Ann Dermatol Venereol; 2020 Apr; 147(4):279-284. PubMed ID: 31879092
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
[TBL] [Abstract][Full Text] [Related]
3. Locally advanced head and neck squamous cell carcinoma and melanoma simultaneously treated with pembrolizumab: an unusual situation.
Mora-Fernández V; Boada A; Manzano JL; Jaka A; Ferrándiz C
Eur J Dermatol; 2020 Dec; 30(6):743-744. PubMed ID: 33237032
[No Abstract] [Full Text] [Related]
4. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma.
Morton CA; Whitehurst C; McColl JH; Moore JV; MacKie RM
Arch Dermatol; 2001 Mar; 137(3):319-24. PubMed ID: 11255332
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
Zhao CY; Hwang SJE; Anforth R; Carlos G; Chou S; Carlino M; Fernández-Peñas P
J Immunother; 2018 Sep; 41(7):343-349. PubMed ID: 29939876
[TBL] [Abstract][Full Text] [Related]
6. [Topical photodynamic therapy in basal and squamous cell carcinoma and penile Bowen's disease with 20% aminolevulinic acid, and exposure to red light and infrared light].
Harth Y; Hirshovitz B
Harefuah; 1998 Apr; 134(8):602-5, 672, 671. PubMed ID: 10911421
[TBL] [Abstract][Full Text] [Related]
7. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.
Saintes C; Saint-Jean M; Brocard A; Peuvrel L; Renaut JJ; Khammari A; Quéreux G; Dréno B
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1006-9. PubMed ID: 24980899
[TBL] [Abstract][Full Text] [Related]
8. [Synergistic effect of anti-PD1 immunotherapy then radiotherapy in advanced basal cell carcinoma].
Malmontet T; Dousset L; Gerard E; Ouhabrache N; Pham-Ledard A; Beylot-Barry M
Ann Dermatol Venereol; 2020 Mar; 147(3):228-232. PubMed ID: 31791649
[TBL] [Abstract][Full Text] [Related]
9. [Oral chemotherapy (sonigegib) of extensive basal cell carcinoma, about 4 cases].
Colné J; Angioi-Duprez K; Granelle F; Maalouf T
J Fr Ophtalmol; 2021 Oct; 44(8):1243-1248. PubMed ID: 34417062
[TBL] [Abstract][Full Text] [Related]
10. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.
Bhutani T; Abrouk M; Sima CS; Sadetsky N; Hou J; Caro I; Chren MM; Arron ST
J Am Acad Dermatol; 2017 Oct; 77(4):713-718. PubMed ID: 28780365
[TBL] [Abstract][Full Text] [Related]
11. Fast-growing cutaneous squamous cell carcinoma in a patient treated with vismodegib.
Poulalhon N; Dalle S; Balme B; Thomas L
Dermatology; 2015; 230(2):101-4. PubMed ID: 25633488
[TBL] [Abstract][Full Text] [Related]
12. Treatment of multiple lesions of Bowen disease with isotretinoin and interferon alfa. Efficacy of combination chemotherapy.
Gordon KB; Roenigk HH; Gendleman M
Arch Dermatol; 1997 Jun; 133(6):691-3. PubMed ID: 9197821
[No Abstract] [Full Text] [Related]
13. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma.
Yin VT; Pfeiffer ML; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2013; 29(2):87-92. PubMed ID: 23446297
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream.
Wu JK; Siller G; Whitehead K
Australas J Dermatol; 2003 May; 44(2):123-5. PubMed ID: 12752186
[TBL] [Abstract][Full Text] [Related]
15. Hearing loss in association with topical imiquimod use for squamous cell carcinoma in situ (Bowen disease).
Rodrigues M; Gamboni SE; Cousins VC; Nixon RL
Australas J Dermatol; 2016 Nov; 57(4):323-324. PubMed ID: 27885662
[No Abstract] [Full Text] [Related]
16. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma.
Fischer S; Hasan Ali O; Jochum W; Kluckert T; Flatz L; Siano M
Oncol Res Treat; 2018; 41(6):391-394. PubMed ID: 29734143
[TBL] [Abstract][Full Text] [Related]
17. Nonmelanoma skin cancer in Japanese ethnic Hawaiians in Kauai, Hawaii: an incidence report.
Chuang TY; Reizner GT; Elpern DJ; Stone JL; Farmer ER
J Am Acad Dermatol; 1995 Sep; 33(3):422-6. PubMed ID: 7657865
[TBL] [Abstract][Full Text] [Related]
18. Topical photodynamic therapy for primary Bowen disease and basal cell carcinoma: optimizing patient selection.
Hambly R; Mansoor N; Quinlan C; Shah Z; Lenane P; Ralph N; Moloney FJ
Br J Dermatol; 2017 Sep; 177(3):e55-e57. PubMed ID: 28028807
[No Abstract] [Full Text] [Related]
19. Imiquimod for superficial and in situ skin malignancy.
Drug Ther Bull; 2009 Oct; 47(10):113-6. PubMed ID: 19809085
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract--a pilot study.
Kacerovská D; Pizinger K; Majer F; Smíd F
Photochem Photobiol; 2008; 84(3):779-85. PubMed ID: 18179625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
